Cohort Data From TRANSCEND-CLL-004 of Liso-Cel: William G. Wierda, MD


The associate professor of medicine from MD Anderson Cancer Center discussed data from the phase 1 cohort of liso-cel combined with ibrutinib.

This content originally appeared on our sister site, OncLive.

William G. Wierda, MD, discusses data from the following presentation:

  • TRANSCEND-CLL-004 phase 1 cohort of lisocabtagene maraleucel combined with ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia (R/R CLL/SLL). (Wierda EG, et al. iwCLL 2021; September 17-20, 2021)
    • Recent studies in patients with R/R CLL suggest that CD19-directed CAR (chimeric antigen receptor) T-cell therapy combined with ibrutinib improves response rates with CTL119 and JCAR014 (Gill SI, et al. Blood. 2018;132:298; Gauthier J, et al. Blood. 2020;135:1650-60). This study reports initial safety and preliminary efficacy from the phase 1 lisocabtagene-maraleucel and ibrutinib combination cohort of the ongoing phase 1/2 TRANSCEND-CLL-004 study (NCT03331198) in patients with R/R CLL/SLL.
    • Eligible patients with CLL/SLL met ≥1 of the following: 1) received ibrutinib and progressed at time of study enrollment; 2) had high-risk features and received ibrutinib for ≥6 months with less than a complete response (CR); 3) had a Bruton tyrosine kinase (BTK) or PLCγ2 gene mutation, with or without progression on ibrutinib; 4) had received prior ibrutinib with no contraindication to reinitiating ibrutinib.
    • Primary end points were safety and to determine the recommended dose of lisocabtagene-maraleucel in combination with ibrutinib for R/R CLL/SLL; overall response rate (CR + CR with incomplete blood count recovery [CRi] + partial response (PR) and pharmacokinetics were exploratory end points.
    • Efficacy results:
      • At data cutoff, 23 patients received lisocabtagene-maraleucel (DL1, n = 4; DL2, n = 19) with ibrutinib. Median age was 61 (range, 50-77) years, and 22 patients (96%) had high-risk cytogenetics (del[17p], n = 9; TP53 mutation, n = 8; complex karyotype, n = 10).
      • Patients had a median of 4 (range, 1-10) prior therapies. All patients were R/R to prior ibrutinib; 12 patients (53%) had prior BTK inhibitor and venetoclax therapy.
      • Patients received lisocabtagene-maraleucel infusion at 50 × 106 (dose level [DL]1) or 100 × 106 (DL2) CAR + T cells.
      • 21 patients (95%) responded to therapy, including 13 (59%) who achieved CR/CRi and 8 (36%) who achieved PR
      • Deepening of response was observed in 4 patients who initially had a PR and improved to a CR at a later assessment.
      • No patients had PD during the first month after lisocabtagene-maraleucel
      • All responders (n = 21/22) achieved a response by Day 30 after lisocabtagene-maraleucel.
      • Among 18 patients with ≥6 months of follow-up, 83.3% (n = 15/18) maintained or improved response from Day 30.
      • Median progression-free survival was not reached (NR) (95% CI, 12.62—NR).
      • Median duration of response was NR (95% CI, NR—NR).
    • Safety results:
      • The combination of lisocabtagene-maraleucel and ibrutinib was well tolerated, with no reported dose-limiting toxicities.
      • No grade 5 adverse events or grade 4 or 5 cytokine release syndrome or neurological events were reported.
      • Grade 3/4 ibrutinib-related treatment-emergent adverse events included neutropenia/neutrophil count decrease (n = 6), anemia (n = 4), thrombocytopenia (n = 2), atrial fibrillation (n = 1), hypertension (n = 1), lung infection (n = 1), and staphylococcal infection (n = 1).
    • No clear difference in safety was observed between dose levels, and DL2 was selected as the recommended dose expansion of lisocabtagene-maraleucel and ibrutinib in patients with R/R CLL/SLL. Heavily pretreated, refractory patients with R/R CLL/SLL had rapid, high overall response rates and achieved undetectable minimal residual disease with lisocabtagene-maraleucel and ibrutinib treatment. Because of encouraging preliminary results, we continue to evaluate the impact of lisocabtagene-maraleucel combined with ibrutinib on efficacy and safety in this actively enrolling clinical trial.
Related Videos
Brian Van Tine, MD, PhD, on Looking Ahead on Cell Therapy for Sarcomas
Dilsher Dhoot, MD, on a Promising Start With Diabetic Retinopathy Gene Therapy RGX-314
J. Andrew Livingston, MD, on Forging Forward With Novel Sarcoma Trials
Shankar Musunuri, PhD, on Gene Modifier Therapy vs Gene Replacement Therapy for IRDs
Pat Furlong, BSN, RN, on the State of Gene Therapy in Muscular Dystrophy
Michael Kelly, PhD, on Continuing Progress With Gene Therapy in Muscular Dystrophy
Related Content
© 2023 MJH Life Sciences

All rights reserved.